Acadia Healthcare stock holds Buy rating at UBS on reduced 2026 capex
PositiveFinancial Markets

Acadia Healthcare has received a Buy rating from UBS, which is a positive sign for investors. This rating comes as the company has reduced its capital expenditures for 2026, indicating a more cautious and strategic approach to its financial planning. This move is significant as it reflects Acadia's commitment to maintaining strong performance while managing costs effectively, making it an attractive option for those looking to invest in the healthcare sector.
— Curated by the World Pulse Now AI Editorial System